Underreporting of Neutropenic Toxicity Associated With Current Treatment Regimens for Selected Hematologic Malignancies
Treatment-Related Neutropenia Is Under-Reported in Hematologic Malignancies
SA Gregory, S Abella, T Moore
Yes
20110601
2011 Jul 1
Community Oncology
Yes
Underreporting of Neutropenic Toxicity Associated With Current Treatment Regimens for Selected Hematologic Malignancies
Community Oncology. 2011 Jul 1;[Epub Ahead of Print], SA Gregory, S Abella, T Moore
Abstract
Abstract
Most chemotherapy regimens considered standard of care for treating hematologic malignancies are myelosuppressive. They include chemotherapy regimens recommended by the National Comprehensive Cancer Network (NCCN),1 such as cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to treat non-Hodgkin lymphoma (NHL) 2,3; fludarabine plus cyclophosphamide (FC) to treat chronic lymphocytic leukemia (CLL)4,5; and escalated-dose bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine,...
